Affimed N.V. (AFMD): VRIO Analysis [Mar-2026 Updated]

Is Affimed N.V. (AFMD) truly positioned for sustainable success? This VRIO analysis cuts straight to the core, distilling whether its current resources offer a fleeting edge or a durable competitive advantage based on Value, Rarity, Inimitability, and Organization. Discover the critical findings that determine Affimed N.V. (AFMD)'s future market strength and strategic viability right below.

Affimed N.V. (AFMD) - VRIO Analysis: First Core Capabilities / Resources: ROCK® Platform Technology

You’re looking at the core engine of Affimed N.V. - the ROCK® Platform Technology - and trying to figure out if it was a sustainable moat or just a very expensive engine that ran out of fuel. Honestly, the answer is complex, but the final outcome is clear: the technology had promise, but the financial structure supporting it did not last through 2025.

Value: Enabling Targeted Tumor Killing

The platform’s value proposition was solid: it enabled the predictable generation of customized Innate Cell Engager (ICE®) molecules designed for tumor-targeted killing. This is a big deal because it aims to harness the patient’s own innate immune cells, like Natural Killer (NK) cells, to fight cancer more effectively. Think of it as building a highly specific key (the ICE® molecule) for a very stubborn lock (the tumor).

For example, the AFM24 program, built on this tech, showed an Objective Response Rate (ORR) in certain Non-Small Cell Lung Cancer (NSCLC) cohorts, with median Progression Free Survival (PFS) reported around 5.9 months based on data presented in late 2024 for a data cut in November 2024. That level of activity in heavily pre-treated patients demonstrates inherent value.

Rarity: A Unique Design Approach

The specific design and engineering of the ROCK® platform to engage innate immune cells is relatively unique in the crowded field of immuno-oncology. It’s not just another T-cell engager; it’s focused on NK cells, which is a distinct approach. This proprietary nature made it rare, at least in terms of its specific molecular architecture and engineering pathway.

Imitability: Specialized Expertise Required

Replicating this technology would be moderately difficult. It requires deep, specialized protein engineering expertise and years of iterative development - the kind of institutional knowledge that doesn't transfer easily. It’s not something a competitor could just buy off the shelf; they’d need to hire away key personnel and spend significant time in the lab refining the process.

Organization: The Fatal Flaw

Here’s where the story turns south. The organization was definitely focused on leveraging this platform for multiple pipeline assets, including AFM13, AFM24, and AFM28. However, the company ultimately failed to secure the long-term financial viability needed to see these assets through. As of September 30, 2024, the cash position was only €24.1 million, which management projected would finance operations into Q4 of 2025. That runway proved insufficient.

The organization’s inability to secure further funding or partnerships to extend operations past that point is the critical failure point.

• Filed for insolvency on May 13, 2025.
• Nasdaq trading suspended on May 20, 2025.
• Delisting effective May 21, 2025.

Competitive Advantage: Temporary at Best

The platform’s potential was high, suggesting a temporary competitive advantage based on its technical superiority. But a competitive advantage is only sustained if the company can keep the lights on and keep developing the product. Since the organization could not sustain operations past the projected Q4 2025 timeline, the advantage was, by definition, temporary.

Here’s the quick math: a cash runway into Q4 2025, followed by insolvency in May 2025, shows the financial planning or fundraising efforts fell short of the required timeline for platform maturation.

The VRIO assessment for the ROCK® Platform Technology looks like this:

What this estimate hides is the value of the underlying intellectual property, which may still be licensed or sold, but the operational advantage tied to Affimed N.V. itself is gone.

Finance: draft a memo detailing the IP asset valuation post-insolvency filing by next Tuesday.

Affimed N.V. (AFMD) - VRIO Analysis: Second Core Capabilities / Resources: Innate Cell Engager (ICE®) Molecule Design

The ICE® Molecule Design capability is assessed based on the framework of Value, Rarity, Imitability, and Organization (VRIO).

Value: Creates molecules that specifically target CD16A on innate immune cells to destroy tumor cells.

The platform demonstrated specific clinical efficacy in target indications. For instance, lead asset AFM13 showed an 94% Overall Response Rate (ORR) and 71% Complete Response (CR) in a specific patient cohort related to CD30+ lymphomas. The platform has treated nearly 400 patients with proprietary ICE® molecules to date.

Rarity: The specific ICE® format, which leverages innate immunity, is a distinct approach compared to standard CAR-T or bispecifics.

The approach is distinct due to its focus on CD16A engagement of innate immune cells. The pipeline includes multiple assets leveraging this core technology:

• AFM13 (CD30/CD16A)
• AFM24 (EGFR/CD16A)
• AFM28 (CD123/CD16A)

Imitability: High initial barrier, but competitors can develop similar multi-specific formats over time.

The initial development of the proprietary format created a time-based barrier. The company's pipeline progression reflects this investment in the technology:

Organization: The company treated ICE® generation as a core competency, applying it across its pipeline.

Organizational focus is evidenced by sustained investment in R&D to advance the pipeline. Research and development expenses for the quarter ended March 31, 2023, were €29.5 million, an increase of 60.7% from the prior year, primarily due to development costs for AFM13 and AFM24 programs.

Competitive Advantage: Temporary; demonstrated clinical proof of concept, but not sufficient to prevent insolvency.

Clinical proof of concept was demonstrated across hematological and solid tumors. However, financial stability was challenged:

• As of September 30, 2024, cash, cash equivalents and investments totaled €24.1 million.
• The projected cash runway, based on operating plans, extended into Q4 2025.
• Net loss for Q3 2024 was €15.1 million, or €0.94 loss per common share.

Affimed N.V. (AFMD) - VRIO Analysis: Third Core Capabilities / Resources: AFM13 (Lead Clinical Asset)

Value: Demonstrated unprecedented efficacy against CD30-positive lymphomas in clinical settings.

• Overall Response Rate (ORR) of 92.9% in 42 heavily pretreated patients with relapsed/refractory lymphoma treated with AFM13-NK combination therapy.
• Complete Response (CR) rate of 66.7% in the same patient group.
• In patients with Hodgkin lymphoma (n=27), ORR was 97.3% and CR was 73%.
• Patients were refractory to brentuximab vedotin and anti-PD1 immune checkpoint inhibitors.
• Two-year Event-Free Survival (EFS) rate of 26.2% and Overall Survival (OS) rate of 76.2% at a median follow-up of 20 months.

Rarity: High, as it showed strong activity in a heavily pre-treated population.

• Median of 7 prior lines of therapy for patients in the Phase 1 trial (NCT04074746).
• Median age of trial participants was 43 years.
• In the LuminICE-203 dose-finding part, median prior treatment lines was 4.5 (range 2–13), including previous stem cell transplant in 58% of patients.

Imitability: Low for the specific molecule, but the mechanism is imitable by other ICE® developers.

• AFM13 is a bispecific antibody targeting CD16A on NK cells and CD30 on lymphoma cells.
• The mechanism involves activating NK cells to kill CD30+ cells.
• The technology involves pre-complexing NK cells with AFM13 to give them CAR-like properties against CD30-positive cells.

Organization: Organization was focused on advancing AFM13, including combination studies with allogeneic NK cells.

• The development included an Investigator Sponsored Trial (IST) led by MD Anderson Cancer Center (AFM13-104).
• The company was on track to submit an IND for the combination trial (AFM13 with Artiva's AB-101 NK cells) in the first half of 2023.
• Phase 2 trial LuminICE-203 (NCT05883449) evaluates AFM13 in combination with AlloNK (AB-101).
• As of June 30, 2024, cash, cash equivalents and investments were €34.4 million, with cash-runway projected into H2 2025.

Competitive Advantage: Temporary; strong data existed, but it was not monetized or advanced to late-stage success before the May 2025 filing.

• Data published in Nature Medicine in April 2025 showed high efficacy.
• As of Q3 2024, cash balance was €24.1 million, with operations expected into Q4 2025.
• The company was anticipating decisions regarding taking the doublet into a registration-directed trial by early, probably first quarter, 2025.

Affimed N.V. (AFMD) - VRIO Analysis: Fourth Core Capabilities / Resources: AFM24 (Clinical Asset)

Value

AFM24 demonstrated activity in heavily pretreated populations:

• In EGFR mutant (EGFRmut) NSCLC patients (17 in PPS) combined with atezolizumab, an Overall Response Rate (ORR) of 24% (1 Complete Response (CR), 3 Partial Responses (PRs)) was observed.
• Disease Control Rate (DCR) was 71% in the EGFRmut NSCLC cohort.
• Median Progression-Free Survival (PFS) was 5.6 months in the EGFRmut NSCLC cohort.
• 29% (5) of EGFRmut NSCLC patients were on treatment for over 10 months.

In a separate gastric cancer study, one patient with signet-ring cell mGC achieved a Partial Response (PR) lasting ~8 months and continued for more than 14 months in total.

Rarity

The asset is a bispecific, tetravalent Innate Cell Engager (ICE®) binding CD16A and EGFR. In the Phase 1, 4 confirmed responses (1 CR, 3 PRs) were seen in 15 heavily pre-treated patients with AFM24 monotherapy. The Recommended Phase 2 Dose (RP2D) was established at 480 mg weekly.

Imitability

The FDA granted Fast Track designation to the combination for NSCLC EGFRwt after progression on PD(L)1 and platinum-based chemotherapy.

Organization

The company was actively evaluating AFM24 in the AFM24-102 trial (NCT05109442).

• As of September 30, 2024, cash, cash equivalents, and investments totaled €24.1 million.
• Cash runway was projected into Q4 2025.
• Research and development expenses for Q3 2024 were €10.1 million, down from €21.5 million in Q3 2023.
• Net loss for Q3 2024 was €15.1 million.

Competitive Advantage

The NSCLC EGFRwt cohort had 43 patients in the Full Analysis Set (FAS) as of November 14, 2024. Future development planned to use a 720 mg weekly dose, based on exposure-response analysis.

Affimed N.V. (AFMD) - VRIO Analysis: Fifth Core Capabilities / Resources: AFM28 (Clinical Asset)

Value: Presented a differentiated profile in vitro for treating Acute Myeloid Leukemia (AML).

• Induction of tumor cell killing in vitro against CD123-positive cells irrespective of mutational status.
• Demonstrated ability to destroy CD123-positive tumor cell lines and primary leukemic cells via antibody-dependent cell-mediated cytotoxicity (ADCC).
• Depletion of CD123-positive leukemic stem cells and progenitor cells while sparing healthy cells in ex vivo bone marrow samples.

Rarity: Moderate; AML is a crowded space, but a differentiated ICE® profile offers a niche advantage.

• AFM28 is a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A.
• Targeting CD123 is acknowledged to hold significant untapped promise in developing better AML therapies.

Imitability: Moderate; requires specific in vitro and early clinical validation to prove superiority.

The asset's imitable barrier is based on the proprietary ROCK® platform technology and the specific binding profile of the molecule.

Organization: The company was running a Phase 1 dose-escalation study for AFM28.

• The study is the first-in-human Phase 1, open-label, non-randomized multiple ascending dose escalation study (AFM28-101).
• The goal of dose escalation is to establish the Maximum Tolerated Dose (MTD) and/or one or more Recommended Phase 2 Doses (RP2D).
• Enrollment was completed in the sixth and final cohort as of June 2024.
• As of September 30, 2024, cash, cash equivalents, and investments totaled €24.1 million, with a projected cash runway into Q4 2025.
• Research and development expenses for the year ended December 31, 2023, were €95.0 million.

Competitive Advantage: Not sustained; this asset was in the earliest clinical stage and required substantial investment.

Affimed N.V. (AFMD) - VRIO Analysis: Sixth Core Capabilities / Resources: Established Clinical Proof of Concept Data

Value: Data validating the ICE® strategy across both hematologic and solid tumors with a strong safety profile.

• AFM13 combination with AlloNK® (AB-101) in treatment-refractory Hodgkin Lymphoma (HL) patients showed an 85.7% ORR with 4 CRs in the first 7 patients.
• AFM13 in combination with cord blood-derived NK cells (cbNK) in CD30-positive relapsed or refractory (r/r) lymphomas achieved a 94.4% objective response rate and a 72.2% complete response rate in 36 patients treated at the recommended Phase 2 dose level (RP2D).
• The AFM13/cbNK regimen demonstrated a good safety and tolerability profile with no cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) or graft versus host disease (GVHD) of any grade.
• AFM24 combination with atezolizumab in 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/L1 treatment showed a 71% Disease Control Rate (DCR).
• AFM28 monotherapy in a Phase 1 dose-escalation study reported a 33% CR/CRi rate in 6 patients treated at dose level 6 (300mg weekly).
• Nearly 400 patients have been treated with proprietary ICE® molecules to date.

Rarity: High; having clinical proof of concept for all three innate cell engagers is a significant de-risking milestone.

Imitability: Low; this specific dataset is proprietary and cannot be replicated without running the same trials.

The proprietary nature of the ROCK® platform which predictably generates customized ICE® molecules is the source of this low imitability.

Organization: Management used this data to attract potential partners and justify continued operations.

• Revenue from collaborations, such as the one with Genentech, included $96.0 million in initial upfront and committed funding.
• A partnership with Roivant Sciences Ltd. provided $60 million in upfront consideration.
• As of September 30, 2024, the cash position was €24.1 million, projecting a cash runway into Q4 2025.
• R&D expenses for Q3 2024 were €10.1 million.

Competitive Advantage: Temporary; this data was the primary source of near-term value but was insufficient to secure the necessary financing.

The company filed for the opening of insolvency proceedings on May 13, 2025, leading to a Nasdaq delisting on May 20, 2025.

The stock traded around $0.18 per share as of May 2025.

Affimed N.V. (AFMD) - VRIO Analysis: Seventh Core Capabilities / Resources: Intellectual Property (IP) Portfolio

Value: Provides legal exclusivity over the ROCK® platform, ICE® designs, and specific drug candidates.

The scope and protection afforded by the IP portfolio can be quantified by the following metrics:

Rarity: High; patent thickets around novel modalities are crucial barriers to entry in biotech.

The company's proprietary platform is described as enabling the generation of first-in-class tetravalent, multi-specific immune cell engagers.

Imitability: Low; patents are legally protected and difficult to design around without infringement.

Organization: The legal and R&D teams worked to maintain and expand the patent estate.

• R&D Personnel constituted 62% of the total workforce of 168 employees.
• The Research and Development expenditure in 2022 was $62.3 million.
• The authorized share capital of the company is EUR 7,500,000.
• As of June 30, 2024, the issued share capital was €1,568,076.91, divided into 15,680,769.1 common shares.

Competitive Advantage: Sustained (in theory); the IP remains valuable even post-insolvency, potentially for licensees or acquirers.

The market capitalization as of Q3 2023 was reported as $87.6 million.

Affimed N.V. (AFMD) - VRIO Analysis: Eighth Core Capabilities / Resources: Strategic Partnership Framework

Value: Ability to generate non-dilutive funding and share development risk through collaborations with larger pharma.

The strategic partnership framework aimed to secure significant non-dilutive capital. For instance, the collaboration with Genentech provided $96 million in initial upfront and committed funding as of October 31, 2018. The collaboration with Roivant Sciences Ltd. resulted in $60 million in upfront consideration, comprising $40 million in cash and $20 million of common shares.

Rarity: Moderate; many biotechs seek partnerships, but Affimed's unique platform made its partnership potential distinct.

Imitability: Low; the specific relationships and deal structures are unique to the company's history.

Organization: The CEO explicitly stated efforts to seek collaborations to drive success.

• CEO Adi Hoess described the Genentech partnership as a 'transformational accomplishment for Affimed.'
• CEO Sean Nilan highlighted that pipeline prioritization was driven by investor interest and commercial potential, given the company's limited cash runway.
• As of Q3 2024, the cash balance was €24.1 million, with prior expectations to finance operations into Q4 2025.

Competitive Advantage: Temporary; the ability to partner was present, but the execution to secure a deal that averted insolvency failed.

• The company filed for insolvency proceedings on May 13, 2025.
• Cash and cash equivalents were €72 million on December 31, 2023.

Affimed N.V. (AFMD) - VRIO Analysis: Ninth Core Capabilities / Resources: Experienced Leadership Team (Pre-Insolvency)

Value: Expertise in leading and expanding biotech companies, including navigating clinical development and financing.

Rarity: Moderate; experienced biotech leadership is available, but finding leaders with specific platform success is rarer.

Imitability: Low; specific leadership chemistry and historical success are hard to replicate quickly.

Organization: The team was focused on a strategic transformation and refining focus on clinical priorities.

• The January 2024 strategic restructuring led to a reduction of headcount by approximately 50%.
• Termination expenses incurred during the nine months ended September 30, 2024, totaled €1.6 million.
• As of September 30, 2024, the accumulated deficit was €585.9 million, with total net equity of €17.2 million.

Competitive Advantage: Not sustained; the team could not organize the company to overcome the financial challenges leading to the May 13, 2025 filing for insolvency proceedings in Mannheim, Germany, due to insufficient capital.

Finance: The company announced the filing for insolvency proceedings on May 13, 2025, after fundraising efforts fell short, leading to a determination of overindebtedness. The stock price fell to $0.13 per share, with the stock having fallen 97% over the past year, and the market capitalization dropped to $2.2 million following the filing news.